BioMap Announces Strategic Collaboration with Sanofi to Advance AI-Driven Biologics Discovery

BioMap Announces Strategic Collaboration with Sanofi to Co-develop Cutting-edge AI Modules for Biologics Drug Discovery Using Its AI PlatformSanofi has reached AI-based drug R&D collaborations with multiple companies in the past two years. These companies includeExscientia、Insilico MedicineAndAtomwiseetc.

Traditional AI methods require a large amount of labeled data to make accurate predictions. However, in the life sciences, labeled data is often missing.BioMap's foundational AI model provides insights for multiple downstream task models by using a large model trained on ubiquitous unlabeled data. This approach enables superior predictions from limited data across a range of therapeutic areas, including immunology, neurology, oncology, and rare diseases.

By leveraging BioMap's customized foundational models and AI expertise, as well as Sanofi's proprietary data, computational innovations in protein engineering, and extensive biologics development experience, the two parties aim to create advanced AI models and large protein language models, which will enable biologics design and multi-parameter optimization.

Under the terms of the agreement, BioMap will receive an upfront payment of $10 million and is eligible for payments based on clinical development, regulatory, and commercial milestones, with a total potential value exceeding $1 billion.

Contact Us

Registration is about to close.

Scan to consult immediately

Phone: 13816031174 (Same as WeChat)

Click here to "Read More" to enter the registration and participation channel.